Filter Results:
(611)
Show Results For
- All HBS Web
(1,026)
- People (4)
- News (257)
- Research (611)
- Events (9)
- Multimedia (24)
- Faculty Publications (398)
Show Results For
- All HBS Web
(1,026)
- People (4)
- News (257)
- Research (611)
- Events (9)
- Multimedia (24)
- Faculty Publications (398)
Sort by
- 1994
- Article
The Evolution of Integrative Capability: Innovation in Cardiovascular Drug Discovery
Henderson, Rebecca M. "The Evolution of Integrative Capability: Innovation in Cardiovascular Drug Discovery." Industrial and Corporate Change 3, no. 3 (1994): 607–630.
- August 2020
- Article
A History of Prescription Drug Monitoring Programs in the United States: Political Appeal and Public Health Efficacy
By: A Jay Holmgren, Alyssa Botelho and Allan M Brandt
Prescription drug monitoring programs (PDMPs) have become a widely embraced policy to address the US opioid crisis. Despite mixed scientific evidence on their effectiveness at improving health and reducing overdose deaths, 49 states and Washington, DC have adopted... View Details
Keywords: Health Disorders; Information Technology; Programs; Technology Adoption; History; Government and Politics; Policy; United States
Holmgren, A Jay, Alyssa Botelho, and Allan M Brandt. "A History of Prescription Drug Monitoring Programs in the United States: Political Appeal and Public Health Efficacy." American Journal of Public Health 110, no. 8 (August 2020).
- February 26, 2003
- Article
Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising
By: Joel S. Weissman, David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman and Robert Leitman
Weissman, Joel S., David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman, and Robert Leitman. "Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising." Health Affairs (February 26, 2003).
- June 2020
- Case
Breakthroughs at Blueprint Medicines
By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
- fall 1994
- Article
Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
Henderson, Rebecca M., and Ian Cockburn. "Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery." Journal of Economics & Management Strategy 3, no. 3 (fall 1994): 481–519.
- 2001
- Working Paper
Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery
By: Stefan Thomke and Walter Kuemmerle
- July 2002
- Article
Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery
By: Stefan Thomke and Walter Kuemmerle
Thomke, Stefan, and Walter Kuemmerle. "Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery." Strategic Management Journal 23, no. 7 (July 2002): 619–635.
- Article
Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery
By: Rebecca M. Henderson and Iain Cockburn
Henderson, Rebecca M., and Iain Cockburn. "Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery." Journal of Industrial Economics 46, no. 2 (June 1998): 157–182.
- January–February 2021
- Article
Food and Drug Administration Guidance Documents and New Medical Devices: The Case of Breast Prostheses
By: Rachel E. Weitzman, Ariel Dora Stern and Daniel B. Kramer
As pressure mounts on the Food and Drug Administration (FDA) to speed its review process for novel devices, and budgetary pressures further strain its resources, the critical role of guidance documents in assuring consistent, rigorous, and scientifically grounded... View Details
Keywords: Medical Devices; FDA; Health Care and Treatment; Government Administration; Information; Standards
Weitzman, Rachel E., Ariel Dora Stern, and Daniel B. Kramer. "Food and Drug Administration Guidance Documents and New Medical Devices: The Case of Breast Prostheses." American Journal of Therapeutics 28, no. 1 (January–February 2021).
- spring 1996
- Article
Scale, Scope and Spillovers: The Determinants of Research Productifity in Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
Henderson, Rebecca M., and Ian Cockburn. "Scale, Scope and Spillovers: The Determinants of Research Productifity in Drug Discovery." RAND Journal of Economics 27, no. 1 (spring 1996): 32–59.
- February 1998 (Revised March 2003)
- Teaching Note
Eli Lilly and Company: Drug Development Strategy (A) and (B) TN
By: Stefan H. Thomke and Ashok Nimgade
Teaching Note for (9-698-010) and (9-698-026). View Details
- November 2019
- Case
The Genesis Lab at Novartis
By: Amy C. Edmondson, Ranjay Gulati, Patrick J. Healy and Kerry Herman
Novartis' Genesis Labs program, launched in 2016 as part of Novartis Institutes for Biomedical Research (NIBR), hosted pitch competitions where teams of NIBR scientists proposed ideas to explore that aimed to revolutionize drug discovery. The goal was to break down... View Details
Keywords: Drug Discovery; Health Care and Treatment; Research and Development; Innovation and Invention; Programs; Management
Edmondson, Amy C., Ranjay Gulati, Patrick J. Healy, and Kerry Herman. "The Genesis Lab at Novartis." Harvard Business School Case 620-007, November 2019.
- June 2021
- Supplement
Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (B)
By: Amitabh Chandra and Spencer Lee-Rey
Chandra, Amitabh, and Spencer Lee-Rey. "Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (B)." Harvard Business School Supplement 621-111, June 2021.
- July 2010
- Teaching Note
Metabical: Positioning and Communications Strategy for a New Weight Loss Drug (Brief Case)
By: John A. Quelch and Heather Beckham
Teaching note to case #4240. View Details
- 2022
- Working Paper
Causal Inference During A Pandemic: Evidence on the Effectiveness of Nebulized Ibuprofen as an Unproven Treatment for COVID-19 in Argentina
By: Sebastian Calonico, Rafael Di Tella and Juan Cruz Lopez Del Valle
Many medical decisions during the pandemic were made without the support of causal evidence obtained in clinical trials. We study the case of nebulized ibuprofen (NaIHS), a drug that was extensively used on COVID-19 patients in Argentina amidst wild claims about its... View Details
Keywords: COVID-19; Drug Treatment; Health Pandemics; Health Care and Treatment; Decision Making; Outcome or Result; Argentina
Calonico, Sebastian, Rafael Di Tella, and Juan Cruz Lopez Del Valle. "Causal Inference During A Pandemic: Evidence on the Effectiveness of Nebulized Ibuprofen as an Unproven Treatment for COVID-19 in Argentina." NBER Working Paper Series, No. 30084, May 2022.
- Article
Incidence and Preventability of Adverse Drug Events in the Nursing Home Setting
By: J. H. Gurwitz, T. S. Field, J. Avorn, D. McCormick, S. Jain, M. Eckler, M. Benser, A. Edmondson and D. W. Bates
Gurwitz, J. H., T. S. Field, J. Avorn, D. McCormick, S. Jain, M. Eckler, M. Benser, A. Edmondson, and D. W. Bates. "Incidence and Preventability of Adverse Drug Events in the Nursing Home Setting." American Journal of Medicine 109, no. 2 (2000): 87–94.
- Summer 2021
- Article
The Cost and Evolution of Quality at Cipla Ltd, 1935–2016
By: Muhammad H. Zaman and Tarun Khanna
This article examines the evolution of Indian pharmaceutical manufacturer Cipla towards producing drugs that met the quality standards of European and U.S. regulators. It employs new research in Cipla’s corporate archives, the Creating Emerging Markets database, and... View Details
Keywords: Cipla; Pharmaceuticals; Drug Quality; Generics; Quality; Standards; Information Technology; Cost; Organizational Culture; Business History; Pharmaceutical Industry; India
Zaman, Muhammad H., and Tarun Khanna. "The Cost and Evolution of Quality at Cipla Ltd, 1935–2016." Business History Review 95, no. 2 (Summer 2021): 249–274.
- Article
Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research
By: Rebecca M. Henderson and Iain Cockburn
Henderson, Rebecca M., and Iain Cockburn. "Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research." Journal of Health Economics 20, no. 6 (November 2001): 32–59.
- 2022
- Working Paper
Exploring the Relationship between Team Diversity, Psychological Safety and Team Performance: Evidence from Pharmaceutical Drug Development
By: Henrik Bresman and Amy C. Edmondson
Breakthrough performance in teams requires pooling diverse perspectives and expertise. To realize the potential of diversity, communicating and translating across differences is essential. However, left to their own devices, diverse teams tend to underperform, in part... View Details
Keywords: Teams; Psychological Safety; Groups and Teams; Diversity; Interpersonal Communication; Performance
Bresman, Henrik, and Amy C. Edmondson. "Exploring the Relationship between Team Diversity, Psychological Safety and Team Performance: Evidence from Pharmaceutical Drug Development." Harvard Business School Working Paper, No. 22-055, February 2022.
- Article
Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research
By: Rebecca Henderson and Iain Cockburn
Henderson, Rebecca, and Iain Cockburn. "Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research." Journal of Health Economics 20, no. 6 (November 2001).